Kissling, EstherHooiveld, MariëtteSandonis-Martin, VirginiaMartínez-Baz, IvánWilliam, NaomaVilcu, Ana-MariaMazagatos, ClaraDomegan, Lisade Lusignan, SimonMeijer, AdamMachado, AusendaBrytting, MiaCasado, ItziarMurray, Josephine-L KBelhillil, SylvieLarrauri, AmparoO'Donnell, JoanTsang, Rubyde Lange, MaritRodrigues, Ana PaulaRiess, MaximilianCastilla Catalán, JesúsHamilton, MarkFalchi, AlessandraPozo Sanchez, FranciscoDunford, LindaCogdale, JadeJansen, TessaGuiomar, RaquelEnkirch, TheresaBurgui, CristinaSigerson, DebbieBlanchon, ThierryMartínez Ochoa, Eva MaríaConnell, JeffEllis, Joannavan Gageldonk-Lafeber, RianneKislaya, IrinaRose, Angela McValenciano, MartaI-MOVE-COVID-19 primary care study team2022-04-252022-04-252021Euro Surveill. 2021;26(29):2100670.http://hdl.handle.net/20.500.12105/14166We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.engVoRhttp://creativecommons.org/licenses/by/4.0/COVID-19EuropeSARS-CoV-2Multicentre studyTest-negative designVaccine effectivenessCOVID-19SARS-CoV-2AdultAgedCOVID-19 VaccinesEuropeHumansPrimary Health CareAtribución 4.0 Internacional342966762629210067010.2807/1560-7917.ES.2021.26.29.21006701560-7917Euro Surveillance: bulletin Europeen sur les maladies transmissiblesopen access